Germany · Delayed Price · Currency is EUR Thor Medical ASA Statistics
Total Valuation
FRA:8NN has a market cap or net worth of EUR 131.48 million. The enterprise value is 113.16 million.
| Market Cap | 131.48M |
| Enterprise Value | 113.16M |
Important Dates
The next estimated earnings date is Thursday, February 26, 2026.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 352.99M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +17.08% |
| Shares Change (QoQ) | +30.71% |
| Owned by Insiders (%) | 4.34% |
| Owned by Institutions (%) | 4.66% |
| Float | 115.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15,620.52 |
| PB Ratio | 3.30 |
| P/TBV Ratio | 7.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -22.82 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -18.11 |
Financial Position
The company has a current ratio of 8.87, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.87 |
| Quick Ratio | 8.78 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.12 |
| Interest Coverage | -323.39 |
Financial Efficiency
Return on equity (ROE) is -16.06% and return on invested capital (ROIC) is -10.77%.
| Return on Equity (ROE) | -16.06% |
| Return on Assets (ROA) | -9.08% |
| Return on Invested Capital (ROIC) | -10.77% |
| Return on Capital Employed (ROCE) | -12.01% |
| Revenue Per Employee | 647 |
| Profits Per Employee | -381,412 |
| Employee Count | 9 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -212,953 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +49.78% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +49.78% |
| 50-Day Moving Average | 0.30 |
| 200-Day Moving Average | 0.24 |
| Relative Strength Index (RSI) | 72.72 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:8NN had revenue of EUR 8,417 and -4.96 million in losses. Loss per share was -0.02.
| Revenue | 8,417 |
| Gross Profit | 8,417 |
| Operating Income | -5.39M |
| Pretax Income | -5.17M |
| Net Income | -4.96M |
| EBITDA | -4.36M |
| EBIT | -5.39M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 18.89 million in cash and 732,290 in debt, giving a net cash position of 18.16 million.
| Cash & Cash Equivalents | 18.89M |
| Total Debt | 732,290 |
| Net Cash | 18.16M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 39.86M |
| Book Value Per Share | 0.11 |
| Working Capital | 18.55M |
Cash Flow
In the last 12 months, operating cash flow was -3.74 million and capital expenditures -2.50 million, giving a free cash flow of -6.25 million.
| Operating Cash Flow | -3.74M |
| Capital Expenditures | -2.50M |
| Free Cash Flow | -6.25M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -64,031.96% |
| Pretax Margin | -61,438.92% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:8NN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.08% |
| Shareholder Yield | -17.08% |
| Earnings Yield | -3.77% |
| FCF Yield | -4.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:8NN has an Altman Z-Score of 3.77 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.77 |
| Piotroski F-Score | 2 |